enGene (ENGN) Competitors $3.74 -0.40 (-9.66%) Closing price 05/1/2025 04:00 PM EasternExtended Trading$3.84 +0.11 (+2.81%) As of 05/1/2025 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ENGN vs. RCUS, NRIX, CMRX, CDMO, ELVN, OCS, GYRE, VIR, AVDL, and RCKTShould you be buying enGene stock or one of its competitors? The main competitors of enGene include Arcus Biosciences (RCUS), Nurix Therapeutics (NRIX), Chimerix (CMRX), Avid Bioservices (CDMO), Enliven Therapeutics (ELVN), Oculis (OCS), Gyre Therapeutics (GYRE), Vir Biotechnology (VIR), Avadel Pharmaceuticals (AVDL), and Rocket Pharmaceuticals (RCKT). These companies are all part of the "pharmaceutical products" industry. enGene vs. Arcus Biosciences Nurix Therapeutics Chimerix Avid Bioservices Enliven Therapeutics Oculis Gyre Therapeutics Vir Biotechnology Avadel Pharmaceuticals Rocket Pharmaceuticals enGene (NASDAQ:ENGN) and Arcus Biosciences (NYSE:RCUS) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, media sentiment, profitability, risk, earnings and community ranking. Do analysts recommend ENGN or RCUS? enGene currently has a consensus price target of $23.29, indicating a potential upside of 522.61%. Arcus Biosciences has a consensus price target of $28.38, indicating a potential upside of 228.99%. Given enGene's higher probable upside, equities analysts clearly believe enGene is more favorable than Arcus Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score enGene 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.00Arcus Biosciences 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.00 Which has more risk & volatility, ENGN or RCUS? enGene has a beta of -0.38, indicating that its share price is 138% less volatile than the S&P 500. Comparatively, Arcus Biosciences has a beta of 1.54, indicating that its share price is 54% more volatile than the S&P 500. Is ENGN or RCUS more profitable? enGene has a net margin of 0.00% compared to Arcus Biosciences' net margin of -102.66%. enGene's return on equity of -16.69% beat Arcus Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets enGeneN/A -16.69% -14.27% Arcus Biosciences -102.66%-45.59%-22.38% Which has preferable valuation and earnings, ENGN or RCUS? enGene has higher earnings, but lower revenue than Arcus Biosciences. Arcus Biosciences is trading at a lower price-to-earnings ratio than enGene, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioenGeneN/AN/A-$55.14M-$1.52-2.46Arcus Biosciences$258M3.51-$307M-$3.10-2.78 Do insiders and institutionals hold more shares of ENGN or RCUS? 64.2% of enGene shares are owned by institutional investors. Comparatively, 92.9% of Arcus Biosciences shares are owned by institutional investors. 13.7% of enGene shares are owned by insiders. Comparatively, 12.3% of Arcus Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Does the MarketBeat Community prefer ENGN or RCUS? Arcus Biosciences received 177 more outperform votes than enGene when rated by MarketBeat users. However, 95.24% of users gave enGene an outperform vote while only 65.45% of users gave Arcus Biosciences an outperform vote. CompanyUnderperformOutperformenGeneOutperform Votes2095.24% Underperform Votes14.76%Arcus BiosciencesOutperform Votes19765.45% Underperform Votes10434.55% Does the media refer more to ENGN or RCUS? In the previous week, enGene had 9 more articles in the media than Arcus Biosciences. MarketBeat recorded 13 mentions for enGene and 4 mentions for Arcus Biosciences. Arcus Biosciences' average media sentiment score of 1.19 beat enGene's score of 0.55 indicating that Arcus Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment enGene 5 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Arcus Biosciences 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryenGene beats Arcus Biosciences on 9 of the 16 factors compared between the two stocks. Get enGene News Delivered to You Automatically Sign up to receive the latest news and ratings for ENGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ENGN vs. The Competition Export to ExcelMetricenGeneBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$190.65M$2.95B$5.53B$7.93BDividend YieldN/A1.89%5.11%4.22%P/E Ratio-6.4530.0722.5118.54Price / SalesN/A494.82397.62103.30Price / CashN/A168.6838.1834.62Price / Book0.613.176.734.25Net Income-$55.14M-$72.35M$3.22B$248.18M7 Day Performance-3.86%2.14%1.38%1.03%1 Month Performance-15.77%5.67%2.79%2.70%1 Year Performance-75.59%-23.57%15.41%4.05% enGene Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ENGNenGene3.4033 of 5 stars$3.74-9.7%$23.29+522.6%-76.5%$190.65MN/A-6.4531Analyst ForecastShort Interest ↑Gap DownRCUSArcus Biosciences2.2724 of 5 stars$7.68-2.5%$30.25+293.9%-44.4%$807.46M$258M-2.44500Upcoming EarningsNews CoveragePositive NewsGap DownNRIXNurix Therapeutics1.9233 of 5 stars$10.55+3.0%$30.44+188.6%-14.7%$804.29M$56.42M-3.65300Analyst ForecastCMRXChimerix2.998 of 5 stars$8.55-0.1%$8.53-0.1%N/A$801.56M$212,000.00-9.0990CDMOAvid Bioservices0.7329 of 5 stars$12.50+0.1%$12.25-2.0%+62.9%$799.18M$139.91M-5.23320High Trading VolumeELVNEnliven Therapeutics2.2518 of 5 stars$16.22-1.9%$40.33+148.7%+9.7%$794.85MN/A-8.5450News CoveragePositive NewsGap DownOCSOculis2.8636 of 5 stars$18.12-0.8%$30.25+66.9%+38.0%$791.16M$980,000.00-9.392Positive NewsGYREGyre Therapeutics0.0652 of 5 stars$8.40-5.4%N/A-32.6%$786.34M$105.76M168.0040Upcoming EarningsNews CoverageVIRVir Biotechnology2.4419 of 5 stars$5.61+2.0%$33.57+498.4%-30.4%$769.37M$63.71M-1.43580AVDLAvadel Pharmaceuticals2.3805 of 5 stars$7.96-0.9%$19.88+149.7%-53.0%$769.17M$169.12M-10.0870Upcoming EarningsPositive NewsRCKTRocket Pharmaceuticals4.6753 of 5 stars$7.17+13.3%$43.00+499.7%-65.1%$764.54MN/A-2.61240Upcoming EarningsHigh Trading Volume Related Companies and Tools Related Companies RCUS Competitors NRIX Competitors CMRX Competitors CDMO Competitors ELVN Competitors OCS Competitors GYRE Competitors VIR Competitors AVDL Competitors RCKT Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ENGN) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredTrump Orders 'National Digital Asset Stockpile'Billionaires Rush Into Digital Banking Token Three massive forces are converging right now, creating what c...Crypto 101 Media | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding enGene Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share enGene With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ENGN Stock Free ENGN Stock Alerts